ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
T Cell-Independent Role of PD-L1 in Kidney Repair: Mitigation of Tubular DNA Damage via PD-L1/BRCA1 Interaction Following AKI.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles mediate immune regulation in acute kidney injury.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Acute kidney injury (AKI) occurs in the patients undergoing anti-programmed cell death protein 1-ligand 1 (PD-L1) therapy, indicating that PD-L1 may play a critical role in maintaining renal homeostasis. However, the precise role and mechanism of PD-L1 in AKI remains largely elusive. In this study, we found that PD-L1 was primarily expressed in proximal tubules and significantly upregulated in both murine models of AKI and renal biopsy samples from AKI patients. Genetic specific deletion of PD-L1 in mouse tubular epithelial cells (TECs) exacerbated renal injury in ischemia-reperfusion injury-induced AKI. Mechanistically, PD-L1 was found to interact with BRCA1 and increase BRCA1 expression to safeguard TECs against DNA damage, thereby promoting cellular proliferation and suppressing apoptosis. To translate these findings into a potential therapeutic strategy, we developed a CGA-functionalized extracellular vesicle delivery system for targeted delivery of PD-L1 to injured TECs. This system efficiently restored PD-L1 expression and alleviated DNA damage of TECs in both TEC-specific PD-L1 knockdown and T-cell knockout AKI mouse models. Collectively, these findings uncover a novel function of PD-L1 in promoting adaptive TEC repair through BRCA1 interaction, independent of its canonical immunomodulatory function of T cells, and suggest that PD-L1 supplementation may represent a promising therapeutic strategy for AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.